Great point about selecting the right endpoints, b
Post# of 148158
Regarding the PE and population for LH/post-viral syndrome (PVS), I hope we have good input from the right experts.
Its a shame BP isn't on the team anymore, as I saw a tweet from Dr. Yo saying BP has figured out LH disease (assume with his panels) and has submitted a publication about it:
https://twitter.com/brucep13/status/1327014400587251717
Here is is LH panel index:
https://twitter.com/brucep13/status/1326911302116192256
"The good news is that our new immunologic algorithm can tell without the other testing whether you are a long hauler with 100% sensitivity!!"
https://twitter.com/YoDoctorYo
Quote:
Dr. Yo
@YoDoctorYo
·
3h
#longhaulers #covid19- not just testing but potential treatment solutions coming and a paper to back it all up.
Patterson also claims to have successfully used maraviroc for LHs with patients back to normal in a week, and no side effects (like elevated LFTs).
https://twitter.com/brucep13
Hard not to worry a little bit about these other, cheaper CCR5i drugs from big pharma with more resources.
Leronlimab is clearly better than small molecule inhibitors in HIV (primarily in side effects over a long duration of taking the drugs and the resistance to viral mutation), and hopefully the advantages carry over to other diseases where CCR5i drugs as a class are/may be helpful like Covid-19, cancer, GVHD, NASH, stroke, MS, other autoimmune diseases, LHs/PVS, and on and on ...